0001477932-26-003195
SEC filingOperating losses narrowed 27% year-over-year to -$302K through cost discipline despite zero revenue, though net loss widened to -$500K and cash burn accelerated to -$617K, intensifying liquidity pressures amid going concern risks.
Guided Therapeutics reported no revenue or gross profit in Q1 FY2026, consistent with the prior year, as the Company remains pre-commercialization for its LuViva device. This reflects the ongoing transition from clinical development to market entry, with historical and expected future revenue derived solely from LuViva devices and disposables.
Net income deteriorated 17.1% to -$500K from -$427K, with diluted EPS stable at -$0.01. Non-operating pressures outweighed operating gains, though specific drivers are not quantified in the statements. This widening reflects the challenges of sustaining operations without revenue while pursuing commercialization.